## **Dr. Jean-Charles Chapuis, Ph.D.**

## **Curriculum vitae**

School of Molecular Sciences

Arizona State University

P.O. Box 87-1604

Tempe, AZ 85287

chapuis@asu.edu

###### **Summary**

Highly motivated Ph.D. scientist with years of dynamic leadership skills in oncology, mammalian tissue culture, microscopy and cytotoxic assay developments. Demonstrated capabilities to achieve scientific challenges. Broad range of technical expertise coupled with highly effective communications and interpersonal skills. Love of teaching and sharing knowledge of health sciences .

###### **Unique Research Skills and Professional Achievements**

Years of experience in mammalian cell culture, oncology and assay development.

Cytotoxicity Screening Optimization Scientist. Evaluated biological activities of hundreds of thousands

of novel pharmaceuticals in medium to high-throughput screening programs.

 Expertise in primary culture, established cell lines (adherent and non adherent) as well as *in vivo*

protocols.

Broad based scientific background with thorough hands-on knowledge of anti-angiogenesis, immuno-

therapy, apoptosis, flow cytometry and cell sorting techniques.

Perform recombinant DNA protocols (including DNA and RNA extractions), genotyping

and PCR, electrophoresis , Western, as well as immunoassays (ELISA) and microarrays.

Thrive in a multidisciplinary team environment.

Proven leader and manager.

Excellent organization skills, communications and presentation. High attention to detail.

###### **Professional Experience**

**Associate Research Professor**, ASU, School of Molecular Sciences, 2016 to current.

Head Screening labs of potential new anticancer drugs from marine, insect, and plant natural products. Manage Microbiology laboratories. Drug discovery.

**Senior Research Scientist,** ASU, School of Molecular Sciences (formerly Chemistry & Biochemistry Department), 2010 to 2016.

Head Screening labs of potential new anticancer drugs from marine, insect, and plant natural products. Manage Microbiology laboratories.

**Senior Research Scientist,** ASU Biodesign Institute, Center for Innovations in Medicine & Mayo MAC5, Mayo Clinic Scottsdale, 2008 to 2010.

Gene fusions as therapeutic biomarkers for malignant diseases. Identification of aberrant peptides. In vitro antibody production. Repository of cancer cell lines. Nucleic acids purification, analysis, amplification, and expression profiling. Proteins isolation and analysis. Microarray Image analysis (GenePix Pro). Exosome purification and analysis.

**Research Collaborator**, Mayo Clinic Scottsdale, 2007 to 2008

Targeted Ultrasound imaging and ultrasound assisted drug delivery.

### Senior Research Scientist, ASU Biodesign Institute, Center for BioEnergetics, 2007 to 2008.

Establish assays to evaluate mitochondrial functions and bioenergetic. Mitochondria as cancer drug targets. Mitochondrial disease. Targeted Ultrasound imaging and ultrasound assisted drug delivery. Drug discovery.

### Senior Research Professional, ASU Biodesign Institute, Center for Innovations in Medicine, 2006 to 2007.

Cancer Eradication Project, tumor immunology, ELISA, molecular biology, Western, PCR. Identify substances that stimulate the immune system. Frameshift mutations. “Gene Gun Therapy”. Tumor vaccines. In vivo small animal protocols. Small peptides, syn-bodies (synthetic antibodies) bio-evaluation.

**Senior Research Professional**, ASU, Biodesign Institute, Center for Cancer Research, 2003 to 2007.

**Section Head,**

Head the Cancer Cell Biology Department for the Center for Cancer Research providing in-house biological screening assays to 30 or more organic and natural product chemists.

**Associate Research Professional**, Arizona State University, Cancer Research Institute, 1997 to 2003.

Developed process for medium to high-throughput screening of increasing amounts of biological samples.

Provide technical leadership to research team in the development of new assays and screening technologies.

Evaluate purified drugs and derivatives using anti-angiogenesis, apoptosis assays, flow cytometry as well as protein and expression assays.

**Assistant Research Professional**, Arizona State University, Cancer Research Institute, 1991 to 1997.

Implement a medium scale screening system of natural products. An array of cytotoxicity assays using human tumor cell lines and murine lymphoblastoid cells is performed routinely to obtain the bio-guided purification of potential new anticancer drugs from marine natural products.

**Postdoctoral Research Associate**, University of Rochester, Cancer Center, Experimental Therapeutics Division & Radiation Oncology, Rochester, NY, 1989 to 1991.

Study tumor cell heterogeneity and its impact on anticancer therapies.

**Research Assistant**, University of Lausanne, School of Pharmacy, Institute of Pharmacognosy & Phytochemistry and Swiss Institute for Cancer Research, 1984 to 1988.

Involved in the development of biochemical assays to evaluate plant extracts for antitumor activity against human colon carcinoma cell lines.

### Math and Biology Teacher, College Pierre Viret, Lausanne 1980-84.

###### **Education**

Ph.D. University of Lausanne, Switzerland, 1988

Institute of Pharmacognosy & Phytochemistry, School of Pharmacy

& Swiss Institute for Cancer Research

Thesis: “Screening for Cytoinhibitory Activity of Plants Used in Traditional Medicine

with an In Vitro Test Using a Human Carcinoma Cell Line.”

B.S. University of Lausanne, Switzerland, 1984

Major: Biochemistry & Animal Biology

###### **Honors & Awards**

Swiss National Science Foundation Fellowship, University of Rochester, Cancer Center, 1989.

Junior Investigator Award, 3rd Int. Conference on Interaction of Radiation Therapy and Systemic Therapy, 1990.

Chosen by the National Institute of Health, National Cancer Institute, as the local scientist selected to assist in the screening of potential candidates at the postbaccalaureate and postdoctoral levels during SACNAS (Society for Advancement of Chicanos and Native Americans in Sciences), September 2001, Phoenix, AZ.

###### **Publications**

G. R. Pettit, N. Melody, J.-C. Chapuis, Antineoplastic Agents. 606 The Betulastatins. submitted (2017).

G. R. Pettit, N. Melody, J.-C. Chapuis, Antineoplastic Agents. 605. Isoquinstatins. In press, (2017).

G. R. Pettit, N. Melody, J.-C. Chapuis, The Path of Quinstatin Derivatives to Antibody Drug Conjugates, J. Nat Prod, **80**, 2447-2452, (2017).

G.R. Pettit, N. Melody, and J-C. Chapuis, "Antineoplastic Agents 603. Quinstatins. Exceptional Cancer Cell Growth Inhibitors”, J. Nat Prod. **80**, 692-698 (2017).

J-C. Chapuis, G.M. Cragg, “The Search for Natural Substances with Therapeutic Activity: Summary of a Tribute to ASP Member Pettit”, The ASP Newsletter, **52**, 13-15 (2016).

G.R. Pettit, Q. Ye, J. Knight, F. Hogan, N. Melody, V. Mukku, D. Doubek, J-C. Chapuis, "Isolation and Structure of Cancer Cell Growth Inhibitory Tetracyclic Triterpenes from the Zimbabwean Monadenium lugardae (Euphorbiaceae)", J. Nat Prod., **79**, 1598-603,(2016).

G.R. Pettit, George; J. Searcy, R. Tan, G. Cragg, N. Melody, J. Knight, J-C. Chapuis, "Antineoplastic Agents. 585. Isolation of Bridelia ferruginea Anticancer Podophyllotoxins and Synthesis of 4-Aza-Podophyllotoxin Structural Modifications", J. Nat. Prod., **79**, 507-518, (2016)

G. R. Pettit, J-P. Xu, J-P, J-C. Chapuis, N. Melody, “The Cephalostatins 24. Isolation, Structure and Cancer Cell Growth Inhibition of Cephalostatin 20”, J. Nat. Prod., **78**, 1446-50, (2015).

G. R. Pettit, P.M. Arce, J-C. Chapuis, C.B. Macdonald,“Antineoplastic Agents 600. From the South Pacific Ocean to the Silstatins”, J. Nat. Prod., **78**, 510-523, (2015).

G.R. Pettit, T.H. Smith, P.M. Arce, E.J. Flahive, C.R. Anderson, J-C. Chapuis, J.-P. Xu, T.L. Groy, P.E. Belcher and C.B. Macdonald, “Antineoplastic Agents. 599. Total Synthesis of Dolastatin 16,” J. Nat. Prod., **78**, 476-85, (2015).

G. R. Pettit, B. R. Moser, D. L. Herald, J. C. Knight, J-C Chapuis, X. Zheng “The Cephalostatins 23. Conversion of Hecogenin to a Steroidal 1,6-Dioxaspiro[5,5]-nonane Analogue for Cephalostatin 11,” J. Nat. Prod., **78**, 1067-72 (2015).

G. R. Pettit, R. Tan, R.K. Pettit, D.L. Doubek, J.-C. Chapuis, and C. Weber, “Antineoplastic Agents. 596. Isolation and Structure of Chromomycin A5 from a BeaufortSea Microorganism,” RSC Advances, **5** (12), 9116-9122 (2015).

G. R. Pettit, N. Melody, F. Hempenstall, J-C. Chapuis, T.L. Groy, and L. Williams, “Antineoplastic agents. 595. Structural modifications of betulin and the X-ray crystal structure of an unusual betulin amine dimer,” J. Nat. Prod., ***77***, 863-872, (2014).

G. R. Pettit, Y. Tang, Q. Zhang, G. T. Bourne, F. Hogan, C. Arm, J. C. Knight, R. K. Pettit, J-C. Chapuis, D. Doubek, F. Ward and J. N. A. Hooper, "Isolation and Structure of Axistatins 1-3 from the Republic of Palau Marine Sponge *Agelas axifera*," J. Nat. Prod., ***76***, 420-424, (2013).

G. R. Pettit, R. Tan, G-H. Bao, N. Melody, D. L. Doubek, S. Gao, J-C. Chapuis, and L. Williams,” Antineoplastic Agents. 587. Isolation and Structure of 3-Epipancratistatin from Narcissus cv. Ice Follies1,” J. Nat. Prod., ***75***, 771-773, (2012).

G. R. Pettit, H. J. Rosenberg, R. Dixon, J. C. Knight, E. Hamel, J-C. Chapuis, R. K. Pettit, F. Hogan, B. Sumner, K. B. Ain, and B. B. Trickey-Platt, “Antineoplastic Agents 548. Synthesis of Iodo- and Diiodocomstatin Phosphate Prodrugs," J. Nat. Prod., ***75***, 385-393, (2012).

S.J. Leiris, H.J. Rosenberg, Z.J. Segerman, K.S. Tsosie, J.-C. Chapuis, S.M. Hecht. Synthesis and evaluation of verticipyrone analogues as mitochondrial complex I inhibitors. Bioorg. Med. Chem., **15**, 18,3481 (2010).

R.K. Pettit, G.R. Pettit, E. Hamel, F. Hogan, B.R. Moser, S. Wolf, S. Pon, J.C. Chapuis, and J. M. Schmidt, E-Combretastatin and E-resveratrol structural modifications: Antimicrobial and cancer cell growth inhibitory b-E-nitrostyrenes. *Bioorg Med Chem.*, **17**, 6606-12, (2009).

J. C. Chapuis, R. M. Schmaltz, K. S. Tsosie, M. M. Belohlavek and S. M. Hecht, Carbohydrate Dependent Targeting of Cancer Cells by Bleomycin-Microbubble Conjugates, J. Am. Chem. Soc., **131**, 2438-9 (2009).

J.C. Chapuis, O. Khdour, X. Cai and S.M. Hecht, Synthesis and Characterization of Delta-lac-acetogenins that potently inhibit Mitochondrial Complex I. *Bioorg Med Chem.*, **17**, 2204-9, (2009).

G.R. Pettit, P. Quisdorf, J.A. Fry, D.L. Herald, E. Hamel and J.-C. Chapuis. Antineoplastic Agents. 565. Synthesis of Combretastin D-2 Phophate and Dihydro-combretastin D-2. J. Nat.Prod. **72**, 876-883 (2009).

G.R. Pettit, J. C. Knight, D.L. Herald, F. Hogan and J.-C. Chapuis. Antineoplastic Agents. 570. Isolation and Structure Elucidation of Bacillistatin 1 and 2 from a Marine Bacillus silvestris. J. Nat. Prod. **72**, 366-371 (2009).

G.R. Pettit, S. Hu, J. C. Knight and J.-C. Chapuis. Antineoplastic Agents. 571. Total Synthesis of Bacillistatin 2. J. Nat. Prod. **72**, 372-379 (2009).

R. H. J. Hargreaves, C. L. David, L. J. Whitesell, D. V. LaBarbera, A. Jamil, J.-C. Chapuis, and E. B. Skibo. Discovery of Quinolinediones Exhibiting a Heat Shock Response and Angiogenesis Inhibition, J. Med. Chem., **51**, 2492-2501 (2008).

R. Siles, J. F. Ackley, M. B. Hadimani, J. J. Hall, B. E. Mugabe, R. Guddneppanavar, K. A. Monk, J.-C. Chapuis, G. R. Pettit, D. J. Chaplin, K. Edvardsen, M. L. Trawick, C. M. Garner, and K. G. Pinney. Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents. J. Nat. Prod.*,* ***71*** (3), 313–320 (2008).

G.R. Pettit, F. Hogan, J.-P. Xu, R. Tan, T. Nogawa, Z. Cichacz, R. K. Pettit, J. Du, Q.-H. Ye, G. M. Cragg, C. L. Herald, M. S. Hoard, A. Goswami, J. Searcy, L. Tackett, D. L. Doubek, L. Williams, J. N. A. Hooper, J. M. Schmidt, J.-C. Chapuis, D. N. Tackett, and F. Craciunescu. Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms, J. Nat. Prod. , **71**, 438-444 (2008).

G. R. Pettit, V. J. R. V. Mukku, G. Cragg,‡ D. L. Herald, J. C. Knight, C. L. Herald,† and J.-C. Chapuis Antineoplastic Agents. 558. *Ampelocissus* sp. Cancer Cell Growth Inhibitory Constituents, *J. Nat. Prod*., **71**, 130-133 (2008).

M. A. Elban, J.-C. Chapuis, M. Li, and S.M. Hecht, Synthesis and biological evaluation of cepharadiones A and B and related dioxoaphorines, Bioorg. Med. Chem., **15**, 6119-6125 (2007).

G.R. Pettit, N. Melody, D.L. Herald, J.C. Knight and J.-C. Chapuis, “Antineoplastic Agents 550. Synthesis of 10b(s)-Epipancratistatin from (+)-Narciclasine,” J. Nat. Prod., **70**, 417-422 (2007).

M.D. Minardi, G.R. Pettit, E. Hamel, R.K. Pettit, and J.-C. Chapuis, “Antineoplastic Agents 509. Synthesis of Sodium Fluorcombstatin Phosphate and Related 3-Halo-Stilbenes,” J. Nat. Prod., **68**, 1450-8 (2005).

G.R. Pettit, Q. Zhang, V. Pinilla, H. Hoffmann, D.L. Doubek, J.-C. Chapuis, R.K. Pettit and J.M. Schmidt, « Antineoplastic Agents 534. Isolation and Structure of Sansevistatins 1 and 2 from the African Sansevieria ehrenbergii,” J. Nat. Prod., **68**, 729-33 (2005).

A.B. Smith 3rd, T.M. Razler, G.R. Pettit and J.-C. Chapuis, “(+)-Phorboxazole A synthetic studies. Identification of a series of highly cytotoxic C(45-46) analogues.” Org. Letters, **7**, 4403-6 (2005).

G.R. Pettit, S. Ducki, D.L. Herald, D.L. Doubek, J.M. Schmidt and J.-C. Chapuis, “Antineoplastic Agents 470. Absolute Configuration of the Marine Sponge Bromopyrrole Agelastatin A.” Oncology Research, **15**, 11-20 (2005).

G.R. Pettit, R. Tan, J.S. Northen, D.L. Herald, J.-C. Chapuis and R.K. Pettit, “Antineoplastic Agents. 529. Isolation and Structure of Nootkastatins 1 and 2 from the Alaskan Yellow Cedar Chamaecyparis nootkatensis.” J. Nat Prod., **67**, 1476 (2004).

G.R. Pettit, J.P. XU, D.L. Doubek, J.-C. Chapuis and J.M. Schmidt, “Antineoplastic Agents 510. Isolation and Structure of Dolastatin 19 from the Gulf of California Sea Hare Dolabella auricularia,” Tetrahedron, J. Nat. Prod., **67**, 1252 (2004).

G.R. Pettit, H. Hoffmann, J. McNulty, K.C. Higgs, A. Murphy, D.J. Molloy, D.L. Herald, M.D. Williams, R.K. Pettit, D.L. Doubek, J.N. Hooper, L. Albright, J.M. Schmidt, J.-C. Chapuis, and L.P. Tackett, “Antineoplastic Agents. 380. Isolation and X-ray Crystal Structure Determination of Isoaaptamine from the Republic of Singapore Hymeniacidon sp. and Conversion to the Phosphate Prodrug Hystatin 1.” J. Nat Prod., **67**, 506 (2004).

G.R. Pettit, Y. Meng, P. Gearing, D.L Herald, R.K. Pettit, D.L. Doubek, J.-C. Chapuis and L.P. Tackett, “Antineoplastic Agents 522. Hernandia peltata (Malaysia) and Hernandia nymphaeifolia (Republic of Maldives),” J. Nat. Prod., **67**, 214 (2004).

G.R. Pettit, J.P. XU, J.-C. Chapuis, R.K. Pettit, L.P. Tackett, D.L. Doubek, J.N.A. Hooper and J.M. Schmidt, “Antineoplastic Agents 520. Isolation and Structure of Irciniastatins A and Bfrom the Indo-Pacific Marine Sponge Ircinia ramosa,” J. Med. Chem., **47**, 1149 (2004).

G.R. Pettit, Y. Meng, C.A. Stevenson, J.C. Knight, Z.A. Cichacz, D.L. Doubek, R.K. Pettit, J.-C. Chapuis and J.M. Schmidt, Isolation and Structure of Palstatin from the Amazon Tree Hymeneae palustris,” J. Nat. Prod., **66**, 259 (2003).

A.B. Smith, R.M. Corbett, G.R. Pettit, J.-C. Chapuis, J.M. Schmidt, E. Hamel and M.K. Jung, “Synthesis and Biological Evaluation of a AB-Spiroketal Analogue,” Bioorg. Med. Chem. Lett., **12**, 2039 (2002).

G.R. Pettit, M.P. Grealish, M.K. Jung, E. Hamel, R.K. Pettit, J.-C. Chapuis and J.M. Schmidt, “Antineoplastic Agents. 465. Structural Modification of Resveratrol: Sodium Resverastatin Phosphate”, J. Med. Chem., **45**, 2534 (2002).

G.R. Pettit, N. Melody, D.L. Herald, J.M. Schmidt, R.K. Pettit and J.-C. Chapuis, “Synthesis of 10b (R) -Hydroxypancratistatin, 10b (S) –Hydroxy-1-Epipancratistatin, 10b (S) –Hydroxy-1,2-Diepipancratistatin and Related Isocaostyrils”, Heterocycles, **56**, 139 (2002)

G.R. Pettit, B.R. Moser, M.R. Boyd, J.M. Schmidt, R.K. Pettit and J.-C. Chapuis, “Antineoplastic Agents 460. Synthesis of Combrestatin A-2 Prodrugs.” Anti-Cancer Drug Design, **16**, 185 (2001).

G.R. Pettit, J.-P. Xu, D.E. Gingrich, M.D. Williams, D.L. Doubek, J.-C. Chapuis and J.M. Schmidt, "Antineoplastic Agents 395. Isolation and Structure of Agelagalastatin from the Papua New Guinea Marine Sponge Agelas sp." Chem. Commun., 915 (1999).

G.R. Pettit, B.E. Toki, D.L. Herald, M.R. Boyd, E. Hamel, R.K. Pettit and J.-C. Chapuis, “Antineoplastic Agents 410. Asymmetric Hydroxylation of trans-Combretastatin A-4”. J. Med. Chem. **42**, 1459 (1999).

G.R. Pettit, M.R. Rhodes, D.L. Herald, D.J. Chaplin, M.R. Stratford, E. Hamel, R.K. Pettit, J.-C. Chapuis and D. Oliva, "Antineoplastic Agents 393. Synthesis of the trans-isomer of Combrestatin A-4 Prodrug". Anti-Cancer Drug Design, **13**, 981 (1998).

G.R. Pettit, R. Tan, N. Melody, Z.A. Cichacz, D.L. Herald, M.S. Hoard, R.K. Pettit and J.C. Chapuis, "Antineoplastic Agents 397. Isolation and Structure of Sesterstatins 4 and 5 from Hyrtios erecta (The Republic of Maldives)". Bioorg. Med. Chem. Lett., **8**, 2093 (1998).

A.B. Smith, Q. Lin, G.R. Pettit, J.-C. Chapuis and J.M. Schmidt, "Synthesis and in vitro Cancer Cell Growth Inhibitory Activity of Monocyclic Model Compounds Containing Spongistatin Triene Side-chains." Bioorg. Med. Chem. Lett. , **8**, 567 (1998).

G.R. Pettit, J.K. Srirangam, J. Barkoczy, M.D. Williams, M.R. Boyd, E. Hamel, R.K. Pettit, F. Hogan, R. Bai, J.-C. Chapuis, S.C. McAllister and J.M. Schmidt, "Antineoplastic Agents 365. Dolastatin 10 SAR Probes." Anti Cancer Drug Design, **13**, 243 (1998).

G.R. Pettit, J. McNulty, D.L. Herald, D.L. Doubek, M.R. Boyd, J.-C. Chapuis, J.M. Schmidt, L.P. Tackett, and M.R. Boyd, "Antineoplatic Agents 362. Isolation and X-ray Crystal Structure of Dibromophakellstatin from the Indian Ocean Sponge Phakellia mauritiana.", J. Nat. Prod., **60**, 180 (1997).

G.R. Pettit, M.S. Hoard, D.L. Doubek, J.M. Schmidt, R.K. Pettit, L. Tackett and J.-C. Chapuis, "Antineoplastic Agents 338. The Cancer Cell Growth Inhibitory Constituents of Terminalia arjuna (Combretacea), J. Ethnopharmacology **53**, 57 (1996).

G.R. Pettit, F. Gao, P.M. Blumberg, C.L. Herald, J.C. Coll, Y. Kamano, N.E. Lewin, J.M. Schmidt and J.-C. Chapuis, "Antineoplastic Agents. 340. Isolation and Structural Elucidation of Bryostatins 16-18.", J. Nat. Prod., **59**, 286 (1996).

G.R. Pettit, J.K. Spirangam, J. Barkoczy, M.D. Williams, K.P.M. Durkin, M.R. Boyd, R. Bai, E. Hamel, J.M. Schmidt and J.C. Chapuis, "Antineoplastic Agents 337. Synthesis of Dolastatin 10 Structural Modifications", Anti-cancer Drug Design, **10**, 529 (1995).

G.R. Pettit, Y. Ichihara, G. Wurzel, M.D. Williams, J.M. Schmidt and J.-C. Chapuis, "Isolation ans Structure of Halistatin 3 from the Western Pacific (Chuuk) Marine Sponge Phakellia sp", J. Chem. Soc., Chem. Communi., 383 (1995).

G.R. Pettit, J.P. Xu, Z.A. Cichacz, M.D. Williams, J.-C. Chapuis, R.L. Cerny, "Antineoplastic Agents 323. Isolation and Structure of Phakellistatin 6 from a Chuuk Archipelago Marine Sponge", Bio. & Med. Chem. Lett., **4**, 2677 (1994).

G.R. Pettit, F. Gao, J.M. Schmidt, J.-C. Chapuis, "Isolation and Structure of Axinastatin 5 from a Republic of Comoros Marine Sponge", Bio. & Med. Chem. Lett., **4**, 2935 (1994).

G.R. Pettit, F. Gao, R.L. Cerny, D.L. Doubek, L. Tackett, J.M. Schmidt, J.-C. Chapuis, "Antineoplastic Agents. 278. Isolation and Structure of Axinastatins 2 and 3 from a Western Caroline Island Marine Sponge", J. Med. Chem., **37**, 1165 (1994).

G.R. Pettit, Y. Kamano, C.L. Herald, Y. Fujii, H. Kizu, M.R. Boyd, F.E. Boettner, D.L. Doubek, J.M. Schmidt, J.-C. Chapuis, and C. Michel, "Isolation of Dolastatins 10-15 from the Marine Mollusc Dolabella auricularia", Tetrahedron, **49**, 9151 (1993).

G.R. Pettit, R. Tan, F. Gao, M.D. Williams, D.L. Doubek, M.R. Boyd, J.M. Schmidt, J.-C. Chapuis, E. Hamel, R. Bai, J.N.A. Hooper, and L.P. Tackett, "Isolation and Structure of Halistatin 1 from the Eastern Indian Ocean Marine Sponge Phakellia carteri", J. Org. Chem., **58**, 2538 (1993).

J.-C. Chapuis, P.C. Keng, and D.W. Siemann, "Activity of Etoposide (VP-16) and Teniposide (VM-26) in Exponential and Plateau Phase Human Tumor Cell Cultures", Anti-cancer Drugs, **3**, 245 (1992).

J.-C. Chapuis, P.C. Keng, and D.W. Siemann, "Activity of Etoposide (VP-16) In Human Tumor Cells Under Different Growth Conditions", Intl. J. Radiation Oncol. Biol. Phys., **20**, 373 (1991).

L.A. Decosterd, H. Stoeckli-Evans, J.-C. Chapuis, J.D. Msonthi, B. Sordat, and K. Hostettmann, "New Cell Growth-Inhibitory Cyclohexadienone Derivatives from Hypericum calycinum L.", Helvetica Chimica Acta, **72**, 1833 (1989).

L.A. Decosterd, H. Stoeckli-Evans, J.-C. Chapuis, J.D. Msonthi, B. Sordat, and K. Hostettmann, "New Hyperforin Derivatives from Hypericum revolutum Vahl with Growth-Inhibitory Activity Against a Human Colon Cell Line", Helvetica Chimica Acta, **72**, 464 (1989).

J.-C. Chapuis, "Screening for Cytoinhibitory Activity of Plants Used in Traditional Medicine with an In Vitro Test Using a Human Carcinoma Cell Line, Ph.D. Thesis, Science Faculty, University of Lausanne, Switzerland (1988).

L.A. Decosterd, H. Stoeckli-Evans, J.-C. Chapuis, J.D. Msonthi, and K. Hostettmann, "Isolation of New Cytotoxic Constituents from Hypericum revolutum and Hypricum calycinum by Liquid-Liquid Chromatography", Planta Medica, **560** (1988).

J.-C. Chapuis, B. Sordat, and K. Hostettmann, "Screening for Cytotoxic Activity of Plants Used in Traditional Medicine", J. of Ethnopharmacology, **23**, 273 (1988).

F. Gafner, J.-C. Chapuis, J.D. Msonthi, and K. Hostettmann, "Cytotoxic Naphtoquinones, Molluscidial Saponins and Flavonols from Diospyros Zombensis", Phytochemistry, **26**, 2501 (1987).

A. Marston, J.-C. Chapuis, J.D. Msonthi, B. Sordat, and K. Hostettmann, "Anthracenic Derivatives from Psorospermum febrifugum and their In Vitro Cytotoxicities to a Human Colon Carcinoma Cell Line", Planta Medica, **207** (1986).

A. Marston, J.-C. Chapuis, and K. Hostettmann, "Isolation and Identification of Cytotoxic Anthraquinones and Vismiones from Psorospermum febrifugum Spach, Bulletin de Liaison du Groupe Polyphenols, 321 (1986).

J.-C. Chapuis, A. Marston, B. Sordat, and K. Hostettmann, "Investigation of Medicinal Plants for their Antiproliferative Activities Against a Human Tumor Cell Line", Planta Medica, 553 (1986).

###### **Acknowledgment**

A list of over 50 extra peer-reviewed publications, for which my essential contributions was acknowledged, can be available upon request.